Evidence map›Paper›PMID 31570768›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2020

Malignant transformation of liver fatty acid binding protein-deficient hepatocellular adenomas: histopathologic spectrum of a rare phenomenon.

Juan Putra, Linda D Ferrell, Annette S H Gouw, Valerie Paradis, Arvind Rishi, Christine Sempoux, Charles Balabaud, Swan N Thung, Paulette Bioulac-Sage

Open access · bronzeAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Investigation ofPlants (Basel, Switzerland) · 2024
    Article
  4. Review
  5. Review
  6. Hepatocellular adenoma: Where are we now?World journal of gastroenterology · 2022
    Article
  7. Article
  8. Guidelines for the Treatment of Hepatocellular Adenoma in the Era of Molecular Biology: An Experience-Based Surgeons' Perspective.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2021
    Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 5 countries.

Juan PutraDepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Juan.Putra@sickkids.ca.ORCID http://orcid.org/0000-0002-3487-4641
Linda D FerrellDepartment of Pathology, University of California, San Francisco, San Francisco, CA, USA.
Annette S H GouwDepartment of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Valerie ParadisPathology Department, Beaujon Hospital, Clichy, France.
Arvind RishiDepartment of Pathology, Long Island Jewish Medical Center, New Hyde Park, NY, USA.
Christine SempouxService of Clinical Pathology, Lausanne University Hospital, Institute of Pathology, Lausanne, Switzerland.
Charles BalabaudBaRITOn Bordeaux Research in Translational Oncology, Univ Bordeaux, INSERM UMR1053, F-33000, Bordeaux, France.
Swan N ThungDepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Paulette Bioulac-SageBaRITOn Bordeaux Research in Translational Oncology, Univ Bordeaux, INSERM UMR1053, F-33000, Bordeaux, France.
Université de Bordeaux · FRHôpital Beaujon · FRHospital for Sick Children · CAIcahn School of Medicine at Mount Sinai · USLong Island Jewish Medical Center · USUniversity Medical Center Groningen · NLUniversity of California, San Francisco · USUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The molecular classification of hepatocellular adenomas highlights a distinctive genotype-phenotype correlation. Malignant transformation is an exceptionally rare complication of hepatocyte nuclear factor 1α (HNF1A)-inactivated hepatocellular adenomas. This subtype is characterized by loss of liver fatty acid binding protein immunoexpression. In this study, we characterized the histopathologic spectrum of 13 liver fatty acid binding protein-deficient hepatocellular adenoma cases showing malignant transformation from multiple centers. Clinicopathologic characteristics of these patients were evaluated. Stains for reticulin, liver fatty acid binding protein, beta-catenin and glutamine synthetase were applied to these lesions. Moreover, the findings were compared to patients with β-catenin mutated hepatocellular adenoma. Liver fatty acid binding protein-deficient hepatocellular adenomas with borderline features/carcinoma were seen predominantly in females (77%) with an average age of 46 ± 18 years and multiple lesions (77%; five patients with adenomatosis). Meanwhile, β-catenin mutated hepatocellular adenoma patients with malignant transformation were predominantly male (67%, p = 0.018) with single lesion (86%, p = 0.0009). The largest liver fatty acid binding protein-deficient hepatocellular adenoma nodule in each patient ranged from 4 to 15.5 cm. Loss of liver fatty acid binding protein by immunohistochemistry was noted in all adenoma and borderline/carcinoma components. Features of malignant transformation were pseudoglandular architecture (85%), cytologic atypia (85%), architectural atypia (100%) and lack of steatosis (100%). Other findings included myxoid change (39%), peliosis (46%) and sinusoidal dilatation (46%). Molecular studies confirmed somatic inactivation of HNF1A in 3 cases and absence of TERT promotor and exon 3 CTNNB1 mutations in five cases. To summarize, liver fatty acid binding protein-deficient hepatocellular adenoma with malignant transformation is most frequently seen in female patients with multiple lesions. Most of these lesions demonstrate pseudoglandular architecture, cytologic and architectural atypia, with lack of steatosis. The natural history of these lesions is relatively benign with the exception of disease recurrence in 1 patient.

Indexed as

Adenoma, Liver CellAdolescentAdultAgedbeta CateninBiomarkers, TumorCell Transformation, NeoplasticChromograninsEuropeFatty Acid-Binding ProteinsFemaleGene SilencingGTP-Binding Protein alpha Subunits, GsHepatocyte Nuclear Factor 1-alphaHumansLiver Neoplasmsbeta CateninBiomarkers, TumorChromograninsCTNNB1 protein, humanFABP1 protein, humanFatty Acid-Binding ProteinsGNAS protein, humanGTP-Binding Protein alpha Subunits, GsHepatocyte Nuclear Factor 1-alphaHNF1A protein, humanTelomeraseTERT protein, human

Identifiers

PMID31570768
OpenAlexW2976721221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.